Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Treasury stock
Non - controlling interests
Beginning balance (in shares) at Dec. 31, 2022   42,344,827          
Beginning balance at Dec. 31, 2022 $ (28,208) $ 423 $ 122,633 $ 73 $ (171,757) $ (16) $ 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Share-based compensation from issuance of options and compensation-based warrants 613   613        
Exercise of stock options (in shares)   5,200          
Exercise of stock options 5   5        
Accretion of 15.00% Series C preferred shares (8,879)   (8,879)        
Issuance of warrants 8,607   8,607        
Foreign currency translation adjustment 11     11      
Net loss (24,643)       (24,643)    
Ending balance (in shares) at Mar. 31, 2023   42,350,027          
Ending balance at Mar. 31, 2023 (52,494) $ 423 122,979 84 (196,400) (16) 20,436
Beginning balance (in shares) at Dec. 31, 2023   49,999,345          
Beginning balance at Dec. 31, 2023 (129,184) $ 500 111,982 (411) (261,691) 0 20,436
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Share-based compensation from issuance of options and compensation-based warrants 536   536        
Exercise of stock options (in shares)   182,888          
Exercise of stock options 2   2        
Accretion of 15.00% Series C preferred shares (13,781)   (13,781)        
Issuance of warrants 7,392   7,392        
Foreign currency translation adjustment (203)     (203)      
Net loss (27,954)       (27,954)    
Ending balance (in shares) at Mar. 31, 2024   50,182,233          
Ending balance at Mar. 31, 2024 $ (163,192) $ 500 $ 106,131 $ (614) $ (289,645) $ 0 $ 20,436